Ranolazine in the treatment of chronic stable angina

被引：0
|
作者：
Gustapane, M. [1 ]
Cardillo, M. T. [1 ]
Biasillo, G. [1 ]
Della Bona, R. [1 ]
机构：
[1] Univ Cattolica Sacro Cuore, Ist Cardiol, Pol A Gemelli, I-00168 Rome, Italy
来源：
CLINICA TERAPEUTICA | 2012年 / 163卷 / 03期
关键词：
chronic stable angina; coronary artery disease; ranolazine; LATE SODIUM CURRENT; RAT HEARTS; ISCHEMIC-MYOCARDIUM; EXERCISE TOLERANCE; CONTROLLED-TRIAL; INHIBITION; DILTIAZEM; PECTORIS; PHARMACOKINETICS; AMLODIPINE;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
Coronary artery disease is the leading cause of death in Europe and in the US and angina is the most common symptom associated with stable coronary artery disease. Despite receiving optimal antianginal therapy, based on agents such as beta-blockers, calcium channel antagonists and nitrates, many patients continue to experience angina. Furthermore, the administration of these drugs is limited by adverse effects such as bradycardia or hypotension. Ranolazine is a new antianginal agent, recently approved as add-on therapy in patients with stable angina. This review will focus on its mechanism of action, tolerability, highlighting the clinical benefit coming from its use. Clin Ter 2012; 163(3):231-234
引用
收藏
页码：231 / 234
页数：4
相关论文
共 50 条
  • [31] Pharmacological treatment of chronic stable angina pectoris
    Tarkin, Jason M.
    Kaski, Juan Carlos
    CLINICAL MEDICINE, 2013, 13 (01) : 63 - 70
  • [32] Real-World Data from the Use of Ranolazine in Patients with Stable Angina Pectoris: The RANGER Study
    Olympios, Christoforos
    Stafylas, Panagiotis
    Dermitzakis, Alkiviadis
    Efthimiadis, Ioannis
    Gardikiotis, Alexandros
    Kakouros, Stavros
    Lampropoulos, Stylianos
    Barbetseas, John
    Sourgounis, Angelos
    JOURNAL OF CLINICAL MEDICINE, 2024, 13 (06)
  • [33] Emerging clinical role of ranolazine in the management of angina
    Vadnais, David S.
    Wenger, Nanette K.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2010, 6 : 517 - 530
  • [34] Ranolazine: A novel metabolic modulator for the treatment of angina
    McCormack, JG
    Stanley, WC
    Wolff, AA
    GENERAL PHARMACOLOGY-THE VASCULAR SYSTEM, 1998, 30 (05): : 639 - 645
  • [35] Improvement in Left Ventricular Systolic and Diastolic Performance During Ranolazine Treatment in Patients With Stable Angina
    Figueredo, Vincent M.
    Pressman, Gregg S.
    Romero-Corral, Abel
    Murdock, Elmer
    Holderbach, Pat
    Morris, D. Lynn
    JOURNAL OF CARDIOVASCULAR PHARMACOLOGY AND THERAPEUTICS, 2011, 16 (02) : 168 - 172
  • [36] Update on ranolazine in the management of angina
    Codolosa, J. Nicolas
    Acharjee, Subroto
    Figueredo, Vincent M.
    VASCULAR HEALTH AND RISK MANAGEMENT, 2014, 10 : 353 - 362
  • [37] Cost-utility of ranolazine for the symptomatic treatment of patients with chronic angina pectoris in Spain
    Álvaro Hidalgo-Vega
    Juan Manuel Ramos-Goñi
    Renata Villoro
    The European Journal of Health Economics, 2014, 15 : 917 - 925
  • [38] Effectiveness of ranolazine in patients with type 2 diabetes mellitus and chronic stable angina according to baseline hemoglobin A1c
    Arnold, Suzanne V.
    McGuire, Darren K.
    Spertus, John A.
    Li, Yan
    Yue, Patrick
    Ben-Yehuda, Ori
    Belardinelli, Luiz
    Jones, Philip G.
    Olmsted, Ann
    Chaitman, Bernard R.
    Kosiborod, Mikhail
    AMERICAN HEART JOURNAL, 2014, 168 (04) : 457 - +
  • [39] Cost-Effectiveness of Ranolazine Added to Standard-of-Care Treatment in Patients With Chronic Stable Angina Pectoris
    Kohn, Christine G.
    Parker, Matthew W.
    Limone, Brendan L.
    Coleman, Craig I.
    AMERICAN JOURNAL OF CARDIOLOGY, 2014, 113 (08) : 1306 - 1311
  • [40] A literature review to evaluate the economic value of ranolazine for the symptomatic treatment of chronic angina pectoris
    Vellopoulou, Katerina
    Kourlaba, Georgia
    Maniadakis, Nikos
    Vardas, Panagiotis
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2016, 211 : 105 - 111
12345